+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Open-Angle Glaucoma Therapeutics Market by Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Therapy Type (Combination Therapy, Monotherapy), Route Of Administration - Global Forecast 2025-2030- Product Image
Open-Angle Glaucoma Therapeutics Market by Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Therapy Type (Combination Therapy, Monotherapy), Route Of Administration - Global Forecast 2025-2030- Product Image
Sale

Open-Angle Glaucoma Therapeutics Market by Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Therapy Type (Combination Therapy, Monotherapy), Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666188
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The open-angle glaucoma therapeutics market is driven by ongoing clinical advances, strategic innovation, and evolving care models, with new therapies and technologies enhancing patient management and shaping competitive dynamics for industry leaders.

Market Snapshot: Open-Angle Glaucoma Therapeutics

The Open-Angle Glaucoma Therapeutics Market grew from USD 9.35 billion in 2024 to USD 10.22 billion in 2025. With a projected CAGR of 8.84%, the market is on track to reach USD 15.55 billion by 2030. This growth is propelled by escalating clinical needs, a rise in at-risk populations due to demographic changes, and continuous product innovation, positioning the segment as a critical focus within ophthalmology.

Scope & Segmentation

This report delivers authoritative analysis of the open-angle glaucoma therapeutics market across comprehensive segments, illustrating the breadth of opportunities and challenges for B2B stakeholders:

  • Drug Classes: Alpha agonists, beta blockers (including betaxolol, metipranolol, timolol), carbonic anhydrase inhibitors, fixed dose combinations, prostaglandin analogues (bimatoprost, latanoprost, tafluprost, travoprost), and rho kinase inhibitors.
  • Therapy Types: Combination therapies (such as beta blocker and prostaglandin, carbonic anhydrase inhibitor and beta blocker) and monotherapy approaches.
  • Routes of Administration: Intravenous, oral, and topical delivery formulations.
  • Regions: In-depth geographic analysis includes the Americas (with detailed focus on the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (spanning key economies such as the UK, Germany, and emerging markets), and Asia-Pacific (with particular emphasis on China, India, Japan, Australia, and Southeast Asian countries).
  • Corporate Landscape: Key profiles analyzed include AbbVie Inc.; Novartis AG; Pfizer Inc.; Merck & Co., Inc.; Santen Pharmaceutical Co., Ltd.; Aerie Pharmaceuticals, Inc.; Alcon Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.

Key Takeaways for Senior Decision-Makers

  • Novel therapy classes and targeted drug delivery mechanisms are reshaping clinical practice by improving tolerability and patient outcomes.
  • Digital health tools, such as smart dispensers and adherence-monitoring platforms, are optimizing treatment pathways and fostering data-driven clinical decisions.
  • Strategic collaborations among global pharmaceutical companies, biotech innovators, and academic centers are expediting clinical development and supporting differentiated product launches.
  • Regional dynamics, especially in Asia-Pacific and Latin America, are opening growth avenues through public health initiatives and pricing models adjusted to local infrastructure constraints.
  • Ongoing segmentation insights allow for more personalized therapeutic strategies that enhance both efficacy and patient satisfaction.

Tariff Impact on Therapeutics Supply and Access

Imminent tariff policies for 2025 introduce complexities to the United States supply chain, impacting cost structures and operational reliability. Elevated import duties on ingredients and manufacturing equipment are escalating production expenditures, pressing companies to strengthen domestic sourcing and optimize supplier networks to safeguard continuity and minimize patient disruption. This evolving regulatory landscape requires agile sourcing strategies and contingency planning to ensure market resilience despite increased scrutiny and potential price volatility.

Methodology & Data Sources

The research combines expert interviews with ophthalmologists, clinical trial specialists, and payers, as well as systematic reviews of scientific literature, regulatory filings, government publications, and market disclosures. Data triangulation and expert validation are rigorously applied to ensure accuracy, transparency, and reduced bias across findings.

Why This Report Matters

  • Enables leadership to benchmark therapeutic innovation and anticipate shifts in global competitive dynamics.
  • Delivers actionable insights into segmentation, operational risks, and emerging technologies, supporting data-driven portfolio and investment decisions.
  • Facilitates proactive planning by synthesizing regulatory and market access trends that are shaping patient care and revenue models.

Conclusion

Equipped with segmented analysis, actionable intelligence, and regional insights, this report empowers B2B decision-makers to refine strategies, manage risks, and capitalize on advancements in the open-angle glaucoma therapeutics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of sustained-release microneedle ocular implants for continuous IOP control over months
5.2. Expanding usage of minimally invasive glaucoma surgery combined with next generation drug delivery systems
5.3. Development and commercial launch of Rho kinase inhibitors as first-in-class therapy targeting trabecular meshwork
5.4. Growing investment in gene therapy approaches for long-term modulation of aqueous humor outflow pathways
5.5. Increasing penetration of fixed-dose bimatoprost and netarsudil combinations driven by adherence benefits
5.6. Emergence of digital health platforms integrating home tonometry and AI algorithms for personalized glaucoma management
5.7. Escalating strategic partnerships between biotech firms and ophthalmology leaders for novel peptide therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Open-Angle Glaucoma Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Alpha Agonists
8.3. Beta Blockers
8.3.1. Betaxolol
8.3.2. Metipranolol
8.3.3. Timolol
8.4. Carbonic Anhydrase Inhibitors
8.5. Fixed Dose Combinations
8.6. Prostaglandin Analogues
8.6.1. Bimatoprost
8.6.2. Latanoprost
8.6.3. Tafluprost
8.6.4. Travoprost
8.7. Rho Kinase Inhibitors
9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.2.1. Beta Blocker And Prostaglandin
9.2.2. Carbonic Anhydrase Inhibitor And Beta Blocker
9.3. Monotherapy
10. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Topical
11. Americas Open-Angle Glaucoma Therapeutics Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Open-Angle Glaucoma Therapeutics Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AbbVie Inc.
14.3.2. Novartis AG
14.3.3. Pfizer Inc.
14.3.4. Merck & Co., Inc.
14.3.5. Santen Pharmaceutical Co., Ltd.
14.3.6. Aerie Pharmaceuticals, Inc.
14.3.7. Alcon Inc.
14.3.8. Viatris Inc.
14.3.9. Teva Pharmaceutical Industries Ltd.
14.3.10. Sun Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 22. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 23. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 24. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 89. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 92. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 93. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 94. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 95. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 96. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 97. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 98. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 99. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 102. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 103. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 104. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 105. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 106. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 107. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 110. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 111. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 166. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 167. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 168. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 169. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 172. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 173. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 178. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 179. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 180. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 181. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 182. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 183. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 184. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 185. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 202. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 203. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 204. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 205. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 208. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 209. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 214. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 215. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 216. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 217. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 218. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 219. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 220. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 221. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 262. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 263. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 264. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 265. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 266. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 267. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 268. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 269. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 281. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 286. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 287. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
TABLE 288. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2030 (USD MILLION)
TABLE 289. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 290. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Open-Angle Glaucoma Therapeutics market report include:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.55 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Glaucoma Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Glaucoma Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Open-angle Glaucoma Therapeutics Market 2024-2028 - Product Image

Open-angle Glaucoma Therapeutics Market 2024-2028

  • Report
  • 163 Pages
  • Global
From
Glaucoma Therapeutics - Global Strategic Business Report - Product Image

Glaucoma Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
South & Central America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel - Product Image

South & Central America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

  • Report
  • 126 Pages
From
Primary Open Angle Glaucoma- Pipeline Insight, 2025 - Product Image

Primary Open Angle Glaucoma- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Open Angle Glaucoma Drugs Market

Open-angle glaucoma is a common type of glaucoma often characterized by an increase in intraocular pressure, which can lead to optic nerve damage and, if untreated, loss of vision. Open-angle glaucoma drugs are a subset of optical disorders drugs, aimed specifically at managing this condition. These medications typically strive to decrease intraocular pressure through various mechanisms, such as reducing the production of aqueous humor (the clear fluid in the eye) or increasing its outflow from the eye. The market comprises several classes of drugs, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. Often these drugs are used in combination to achieve better control over eye pressure. Treatment for open-angle glaucoma is a crucial component of the broader optical disorders drugs market, which addresses a spectrum of conditions affecting vision, such as age-related macular degeneration, diabetic retinopathy, and cataracts. While therapies for these conditions can vary widely, the approach to managing open-angle glaucoma is more focused on pressure regulation within the eye to prevent or reduce damage to the optic nerve and maintain the patient's functional vision. Several key players in the open-angle glaucoma drugs market include Pfizer, Allergan (now part of AbbVie), Merck & Co., Novartis, and Santen Pharmaceutical. These companies have stayed at the forefront by offering a diverse portfolio of treatments and by investing in the development Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.